Zirconium silicate

Drug Profile

Zirconium silicate

Alternative Names: Sodium zirconium cyclosilicate; UXSi-9; Ziconite; Zircon; ZS; ZS 9

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator ZS Pharma
  • Class Heavy metals; Minerals; Silicates; Transition elements
  • Mechanism of Action Potassium binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Hyperkalaemia

Most Recent Events

  • 01 Nov 2016 AstraZeneca completes a phase III trial in Hyperkalaemia USA, Australia, Germany, Netherlands, Romania, South Africa, United Kingdom (PO) (NCT02163499)
  • 18 Oct 2016 The US FDA accepts re-submitted NDA for Zirconium silicate for Hyperkalaemia for review
  • 18 Aug 2016 AstraZeneca plans the phase III HARMONIZE Global trial for Hyperkalaemia in Taiwan, South Korea, Japan and Russia (PO, Suspension) (NCT02875834)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top